RecruitingHereditary AngioedemaHAEHereditary Angioedema - Type 1
STOP-HAE: A Phase 3 Study of ADX-324 in HAE
Eligible age
18+ yrs
Accepts
All genders
Locations
12 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This study will evaluate the efficacy and safety of ADX-324 in participants with Type 1 or Type 2 hereditary angioedema. The study will also evaluate safety, pharmacokinetics (PK), pharmacodynamics (PD), and health-related quality of life measures.
Sponsor: ADARx Pharmaceuticals, Inc.
Where it's recruiting
Source: ClinicalTrials.gov · NCT06960213 · last updated 2026-09-10